107.80
+2.91(+2.77%)
Currency In USD
| Previous Close | 104.89 |
| Open | 104 |
| Day High | 108.72 |
| Day Low | 103.9 |
| 52-Week High | 122.2 |
| 52-Week Low | 45.91 |
| Volume | 436,271 |
| Average Volume | 775,283 |
| Market Cap | 7.19B |
| PE | -34.77 |
| EPS | -3.1 |
| Moving Average 50 Days | 105.62 |
| Moving Average 200 Days | 87 |
| Change | 2.91 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,387.46 as of January 14, 2026 at a share price of $107.8. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,177.13 as of January 14, 2026 at a share price of $107.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
GlobeNewswire Inc.
Jan 09, 2026 1:00 PM GMT
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
GlobeNewswire Inc.
Dec 10, 2025 9:01 PM GMT
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that